Japan-based Fujirebio’s test, which helps doctors diagnose Alzheimer’s disease, is intended for patients with signs of cognitive decline.
FDA greenlights marketing of first Alzheimer’s blood test for some patients
May 16, 2025 | 4:14 PM
Japan-based Fujirebio’s test, which helps doctors diagnose Alzheimer’s disease, is intended for patients with signs of cognitive decline.
What should be done to break the impasse in approving Pennsylvania’s budget?